Medicx Fund (MXF) Earns Buy Rating from Liberum Capital

Liberum Capital reissued their buy rating on shares of Medicx Fund (LON:MXF) in a research report released on Wednesday, September 12th.

Separately, Peel Hunt downgraded shares of Medicx Fund to a reduce rating and reduced their price objective for the company from GBX 78 ($1.02) to GBX 72 ($0.94) in a research note on Tuesday, May 22nd.

Shares of MXF traded up GBX 0.01 ($0.00) on Wednesday, hitting GBX 0.80 ($0.01). 323,501 shares of the stock traded hands, compared to its average volume of 412,813. Medicx Fund has a 1 year low of GBX 76.75 ($1.00) and a 1 year high of GBX 92.50 ($1.20).

The business also recently declared a dividend, which was paid on Friday, September 28th. Investors of record on Thursday, August 16th were given a dividend of GBX 1.51 ($0.02) per share. This represents a yield of 1.88%. The ex-dividend date was Thursday, August 16th.

About Medicx Fund

MedicX Fund Limited ("MXF", "MedicX Fund", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 154 properties.

See Also: Hedge Funds – Risk or Reward?

Receive News & Ratings for Medicx Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicx Fund and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply